USFDA2 Jan 2024, 12:42 am
Alembic Pharmaceuticals Receives Multiple Product Approvals from USFDA
AI Summary
Alembic Pharmaceuticals Limited has received various product approvals from the US Food and Drug Administration (USFDA) during the quarter ended December 31, 2023. The company has a cumulative total of 196 ANDA approvals from USFDA, including 170 final approvals and 26 tentative approvals. The approved products include Selexipag Tablets, Rivaroxaban Tablets, and others. The company has requested the exchange to take the above information on record.,
Key Highlights
- Alembic Pharmaceuticals receives multiple product approvals from USFDA
- Company has a cumulative total of 196 ANDA approvals from USFDA
- Selexipag Tablets and Rivaroxaban Tablets are among the approved products